A Comprehensive Genetic Study of Classical Hodgkin Lymphoma Using Ctdna
Matin Salehi(SIB Swiss Institute of Bioinformatics), Davide Rossi(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Alessio Bruscaggin(Institute of Oncology Research), Luca Mazzucchelli(Istituto Cantonale di Patologia), Stefan Hohaus, Lodovico Terzi di Bergamo(Institute of Oncology Research), Georg Stüssi(Institute of Oncology Research), Adalgisa Condoluci(Ente Ospedaliero Cantonale), Marcello Rodari(Humanitas University), Luigi Maria Larocca(Agostino Gemelli University Polyclinic), Renzo Boldorini(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Eleonora Calabretta(Dana-Farber Cancer Institute), Luca Ceriani(St Thomas' Hospital), Maria Cristina Pirosa(Institute of Oncology Research), Eugenio Borsatti(Centro di Riferimento Oncologico), Riccardo Moia(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Pietro Bulian(Centro di Riferimento Oncologico), Michał Kurlapski(University Clinical Centre), Bernhard Gerber, Andrea Rinaldi(IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola), Salvatore Annunziata(Agostino Gemelli University Polyclinic), Martina Di Trani(Humanitas University), Alexandar Tzankov(University of Basel), Deborah Piffaretti(Institute of Oncology Research), Gianluca Gaïdano(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Carmelo Carlo‐Stella(Humanitas University), Stéphane Chauvie(Azienda Sanitaria Ospedaliera S.Croce e Carle Cuneo), Marco Cuzzocrea(Institute of Oncology Research), Anastasios Stathis(Princess Margaret Cancer Centre), Katia Pini(Institute of Oncology Research), Jan Zaucha(University of Dundee), Ilaria Zangrilli(Agostino Gemelli University Polyclinic), Vanessa Cristaldi(Humanitas University), Grzegorz Romanowicz(Gdańsk Medical University), Gabriela Forestieri(Institute of Oncology Research), Valter Gattei(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), C. Giordano(Federico II University Hospital), Gian Mauro Sacchetti(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), F Cavalli(University of Insubria), Simone Bocchetta(Institute of Oncology Research), Armando Santoro(IRCCS Humanitas Research Hospital), Emanuele Zucca(Università della Svizzera italiana), Francesco Corrado(University of Messina), Valeria Spina(Ente Ospedaliero Cantonale), Federico Jauk(Institute of Oncology Research), G. Galimberti(Institute of Oncology Research), Fabrizio Bergesio(Azienda Sanitaria Ospedaliera S.Croce e Carle Cuneo)
Cited by 1
Related Papers
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial
|Journal of Hepatology|2012|821
Advanced pancreatic carcinoma: current treatment and future challenges
|Nature Reviews Clinical Oncology|2010|791